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Abstract
Background: Chronic kidney disease (CKD) in reproductive-age women is accompanied by menstrual and fertility disorders 
and premature menopause.
Objective: We sought to determine nephrologists’ and allied health care providers’ perceptions on management of sex 
hormone status in women with CKD.
Methods: An anonymous, Internet-based survey was sent to nephrology society members from Canada, Australia, New 
Zealand, and the United Kingdom, and the Canadian Association of Nephrology Nurses and Technologists (February-
November 2015). We assessed reported perceptions and management of sex hormone status in women with CKD.
Results: One hundred seventy-five nephrologists (21% response rate) and 121 allied health care providers (30%; 116 nurses, 
5 pharmacists) responded. Sixty-eight percent of nephrologists and 46% of allied providers were between the ages of 30 and 
50 years, and 38% of nephrologists and 89% of allied workers were female. Ninety-five percent of nephrologists agreed that 
kidney function impacts sex hormone status, although only a minority of nephrologists reported often discussing fertility (35%, 
female vs male nephrologists, P = .06) and menstrual irregularities with their patients (15%, female vs male nephrologists, 
P = .02). Transplant nephrologists reported discussing fertility more often than did nontransplant nephrologists (53% vs 30%, 
P = .03). Physicians were more likely to report discussing fertility (33% vs 7.5%, P < .001) and menstrual irregularities (15% 
vs 9%, P = .04) with patients than allied health care providers. Forty-three percent of physicians reported uncertainty about 
the role for postmenopausal hormone therapy in women with CKD.
Conclusion: Nephrologists and allied health care providers recognize an impact of CKD on sex hormones in women but 
report not frequently discussing sex hormone–related issues with patients. Our international survey highlights an important 
knowledge gap in nephrology.
Abrégé
Contexte: Chez les femmes en âge de procréer, l’insuffisance rénale chronique (IRC) peut être associée à des irrégularités 
du cycle menstruel, des problèmes de fertilité et à la survenue d’une ménopause précoce.
Objectifs de l’étude: Cette étude visait deux objectifs. D’abord, on a voulu connaître la manière dont les néphrologues et 
les autres professionnels de la santé perçoivent les troubles hormonaux associés à l’IRC chez les femmes en âge de procréer. 
Ensuite, nous souhaitions établir comment ces perceptions influencent la prise en charge des patientes.
Méthodologie: Entre février et novembre 2015, nous avons fait parvenir un sondage Web anonyme aux membres de la 
Société de néphrologie du Canada, de l’Australie, de la Nouvelle-Zélande et du Royaume-Uni, de même qu’aux membres de 
l’Association canadienne des infirmières et infirmiers et des technologues de néphrologie (ACITN/CANNT). Nous avons 
compilé et analysé les réponses obtenues au sujet des perceptions et de la prise en charge de l’activité hormonale dans le 
suivi des femmes atteintes d’IRC.
Résultats: Un total de 175 néphrologues (taux de réponse de 21 %) et de 123 autres professionnels de la santé, soit 116 
infirmières et 5 pharmaciens (taux de réponse de 30 %) ont répondu au sondage. Les répondants étaient majoritairement 
âgés de 30 à 50 ans (68 % des néphrologues et 46 % des autres professionnels de la santé). Un peu plus du tiers des 
néphrologues étaient des femmes (38 %) alors que ces dernières représentaient la très grande majorité (89 %) des autres 
professionnels de la santé ayant répondu au sondage. La plupart des néphrologues (95 %) ont admis que la fonction rénale 
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perturbe l’activité des hormones sexuelles chez leurs patientes, bien qu’une minorité reconnaissait discuter des enjeux liés 
à la fertilité (35 %) et des irrégularités du cycle menstruel (15 %) avec elles. Dans les deux cas, bien que les différences ne 
soient pas statistiquement significatives, les néphrologues féminines étaient plus nombreuses que leurs collègues masculins 
à aborder ces sujets de façon régulière avec leurs patientes (ratio homme-femme p=0,06 pour l’infertilité, et p=0,02 pour 
les irrégularités du cycle menstruel). De plus, le sondage indique que les néphrologues transplantologues abordent plus 
souvent les questions de fertilité avec leurs patientes que les néphrologues qui ne pratiquent pas de greffes (53 % contre 30 
%, p=0,03). De manière générale, les médecins se montraient plus enclins à discuter des problèmes de fertilité (33 % contre 
7,5 %, p<0,001) et des irrégularités du cycle menstruel (15 % contre 9 %, p=0.04) avec les patientes atteintes d’IRC que les 
autres professionnels de la santé. Enfin, en ce qui concerne le suivi des cas de ménopause précoce, 43 % des médecins se 
sont dits incertains quant au rôle que pourrait jouer l’hormonothérapie post-ménopausique pour les femmes atteintes d’IRC.
Conclusion: De manière générale, les néphrologues et les autres professionnels de la santé admettent que l’activité des 
hormones sexuelles est influencée par la fonction rénale chez les femmes atteintes d’IRC. Néanmoins, ils reconnaissent ne 
pas aborder d’emblée les enjeux de fertilité et les irrégularités du cycle menstruel associés à l’IRC avec leurs patientes. Ainsi, 
ce sondage mené à l’international témoigne d’un écart important entre les connaissances et les pratiques dans le domaine 
de la néphrologie.
Keywords
chronic kidney disease, nephrologist, survey, estradiol, sex hormone, hormone therapy, women
Received January 9, 2017. Accepted for publication June 19, 2017.
1Faculty of Medicine, University of Calgary, Alberta, Canada
2Libin Cardiovascular Institute of Alberta, Calgary, Canada
3Alberta Kidney Disease Network, Calgary, Canada
4Department of Community Health Sciences, University of Calgary, Alberta, Canada
5Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
6Harvard University, Boston, MA, USA
7Royal Free Hospital, University College London, UK
Corresponding Author:
Sofia B. Ahmed, Faculty of Medicine, University of Calgary, 1403-29th St. NW, C210, Calgary, Alberta, Canada T2N 2T9. 
Email: Sofia.Ahmed@albertahealthservices.ca
What was known before
Chronic kidney disease (CKD) is commonly associated with 
menstrual disorders, infertility, and premature menopause. 
Nephrologists are often considered as the primary care pro-
viders by their patients, but perceptions of nephrologists and 
renal allied health care providers on management of these 
issues are currently unknown.
What this adds
While nephrologists and allied health care providers recognize 
the impact of CKD on sex hormone status in women, they 
reported not frequently discussing menstrual disorders, fertil-
ity, and menopause with their female patients with CKD, high-
lighting an important knowledge gap in nephrology.
Introduction
Chronic kidney disease (CKD) affects 8% to 16% of indi-
viduals globally.1 In women with CKD, disruptions in 
gonadotropin-releasing hormone (GnRH) production result 
in an abnormal sex hormone profile, ultimately resulting in 
low levels of estradiol2-4 and commonly leading to early 
menopause, menstrual disorders, and infertility in women 
with both dialysis and non-dialysis-dependent CKD.5 
Fertility rates among women of childbearing age with CKD 
are low,6-9 and complications to both mother and fetus are 
high when pregnancy occurs,9,10 highlighting the importance 
of discussion of the potential risks of contraception11-13 com-
pared with the risks of pregnancy. The mean age at meno-
pause is 4 years earlier in women with end-stage kidney 
disease (ESKD) compared with the general population.14
International guidelines suggest that women with prema-
ture menopause in the general population use hormone ther-
apy (HT) until the median age of natural menopause for 
symptom management,15-18 although this has never been 
addressed in guidelines relevant to the CKD population. 
Studies on the role of HT in the CKD population are limited.19-25 
Given the high prevalence of menstrual, pregnancy, and fer-
tility disorders coupled with the early menopause observed 
in the CKD population, we sought to determine how health 
care providers in nephrology approach management of sex 
hormone status in women with CKD.
Ramesh et al 3
Methods
Survey Development
A survey instrument (Appendix 1) was developed with input 
from a group of 15 physicians (experts in the field of nephrol-
ogy [n = 13], endocrinology [n = 1], and cardiology [n = 1]) 
and nephrology nurses (n = 3). Item generation was devel-
oped through a combination of literature review and consul-
tation with experts in the field as outlined above. An 
assessment of the face validity, clarity, length, and complete-
ness of the survey was performed through semistructured 
interviews (pre-testing) with nephrologists. The instrument 
was pilot tested on 6 nephrologists.
Survey Administration
An e-mail cover letter explaining the purpose of the study and 
a link providing access to the secure, web-based survey were 
sent to 2441 members of the Canadian (n = 285) and Australia 
and New Zealand (n = 850) Nephrology Societies, the British 
Renal Society (n = 1306), and the Canadian Association of 
Nephrology Nurses and Technologists (n = 456) between 
February and November 2015. All physicians and allied 
health care providers (nurses and pharmacists) were recruited 
through memberships to these organizations. The study 
remained open 2 months after the initial e-mail contact. 
Reminder e-mails were sent up to 3 times, each at least 2 
weeks apart. In addition, the survey was included in the 
monthly International Society of Nephrology (n = 9000) elec-
tronic newsletter for July and September 2015. The survey 
was disseminated in June 2015 and again in August 2015 via 
Twitter by the International Society of Nephrology.
Information was collected on demographics, type of 
nephrology practice, perceptions on discussion of fertility, 
menstrual cycle irregularities and menopause with patients, 
and opinions on use of postmenopausal HT in women with 
CKD. The responses for questions were assessed for frequency 
(never, rarely, sometimes, often, or always) or agreement 
(strongly disagree, disagree, neither agree nor disagree, agree, 
strongly agree, or I do not know). In addition, each question 
included an optional free form comment section. Clinical sen-
sibility was assessed by reviewing the comments from the sur-
vey sent to the Canadian Society of Nephrology, and the 
survey was modified to include a question to further assess 
type of practice (adult, pediatric, or both) such that the survey 
link to the British Renal Society, Australian and New Zealand 
Society of Nephrology, the International Society of 
Nephrology, and the Canadian Association of Nephrology 
Nurses and Technologists included a question regarding pedi-
atric versus adult nephrology practice.
Ethics approval for the study was obtained from the 
University of Calgary Conjoint Health Research Ethics 
Board. Participation in the study was voluntary, and informed 
consent was obtained electronically as part of the survey.
Data Analysis
The primary goal was to describe the perceptions of nephrol-
ogists and allied health care providers on the importance and 
frequency of discussing sex hormone status with their female 
patients with CKD, and their opinions on use of HT in 
women with CKD. We compared the responses from female 
and male nephrologists, as it has been reported that physi-
cians use fewer resources to treat the genital-specific condi-
tions of same-sex patients.26 All data were used to conduct 
stratified statistical analyses using the Pearson chi-squared 
test. Further comparisons were made between transplant and 
nontransplant nephrologists, physicians, and allied health 
care workers and geographical location using ordinal logistic 
and logistic regressions. For the qualitative analysis, each 
free form response was analyzed collectively by 2 reviewers 
(S.R. and S.B.A.), comments were reduced to broader themes 
by inductively developing categories, and recurrent ideas 
were grouped into themes which were then reported. There 
was consensus between the 2 reviewers.
Results
Demographics
There were 296 respondents (158 nephrologists, 17 medical 
trainees in nephrology, 121 nephrology allied health care 
providers [116 nurses and 5 pharmacists]) to the survey. The 
average response rate was 21.2% (47%, 8.4%, 1.3%, and 
28%, respectively, for the Canadian Society of Nephrology, 
British Renal Society, Australian and New Zealand Society 
of Nephrology, and Canadian Association of Nephrology 
Nurses and Technologists). In addition, 0.2% of the member-
ship from the International Society of Nephrology responded 
to the survey, though the low response rate was expected due 
to the fact that the Canadian and Australia and New Zealand 
Societies of Nephrology also form part of the International 
Society of Nephrology.
Table 1 summarizes the demographic characteristics of 
the respondents. Sixty-eight percent of the nephrologists 
were between the ages of 30 and 50 years, and 38% of 
nephrologists were female. There was a broad range in terms 
of length of practice with the majority practicing nephrology 
in a clinical and academic setting. Twenty percent of the phy-
sicians were transplant nephrologists. Of the 55 nephrolo-
gists and trainees in nephrology respondents where this 
information was available, 4% of nephrologist respondents 
were primarily involved in pediatric practice.
Forty-six percent of the allied health care providers (nurses 
and pharmacists) were between the ages of 30 and 50 years 
and 89% of them were female. Fifty-six percent of the allied 
health care respondents reported being in nephrology practice 
for greater than 25 years. None of the allied health care respon-
dents worked primarily with a transplant population, and 2% 
reported being primarily involved in pediatric practice.
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Impact of Kidney Disease on Sex Hormones and 
Discussion of Symptoms
The perceptions of nephrologists on sex hormone status and 
kidney function are summarized in Figures 1 to 4. Ninety- 
five percent of the respondents strongly agreed or agreed 
that kidney function has an important effect on sex hormone 
status, but only a third of respondents reported often or 
always discussing fertility and even fewer (15%) reported 
always or often discussing menstrual irregularities with 
their female patients of childbearing age. Although there 
were no statistically significant differences between female 
and male nephrologists in how often they reported discuss-
ing fertility (P = .06), female nephrologists reported more 
frequently discussing menstrual irregularities with their 
patients (P = .02) (Figure 1). Transplant nephrologists were 
more likely to report discussing fertility with their female 
patients (53% transplant vs 30% nontransplant nephrologist, 
P = .03). There were no differences based on geographical 
location of the respondents. As only 4% of the nephrologists 
reported having a mainly pediatric practice, we were unable 
to analyze the difference between adult and pediatric 
nephrologists.
Thirteen percent of respondents provided optional com-
ments. The main themes that emerged from qualitative anal-
yses were that discussions regarding fertility were focused 
on either contraception counseling in the setting of use of 
teratogenic drugs or pre–kidney transplant, or when prescrib-
ing drugs associated with the potential to cause ovarian fail-
ure. In addition, some physicians outlined that discussion of 
fertility with their patients was not warranted because the 
female patients in their practice were mainly older women.
Forty-eight percent of the nephrologists believed their 
female patients of childbearing age wished to discuss fertil-
ity and 15% to discuss menstrual status and menopause. 
Female nephrologists stated that their female patients brought 
up issues about fertility with them more frequently than did 
male nephrologists (P = .03); however, this gender differ-
ence was not observed for patients discussing menstrual sta-
tus or menopause (P = .14; Figure 2). Female patients were 
Table 1. Baseline Characteristics of All Respondents.
Nephrologist and medical trainees Allied health care provider
 All (N = 296)
% Female 
(n = 67)
% Male  
(n = 108) P value (χ2)
% Female  
(n = 108)
% Male  
(n = 13) P value (χ2)
Age, y .04 .18
 <30 5.74 4.63 13.43 1.85 7.69  
 30-40 25.34 34.33 31.48 14.81 15.38  
 41-50 34.12 35.82 36.11 28.7 53.85  
 51-60 30.07 10.45 22.22 50.93 23.08  
 61-70 3.38 5.97 1.85 3.7 0  
 >70 1.35 0 3.7 0 0  
Years of practice .528 .01
 <5 15.88 29.85 19.44 2.78 23.08  
 5-10 16.55 20.9 23.15 6.48 23.08  
 10-15 19.59 23.88 24.07 12.96 15.38  
 15-20 11.15 11.94 10.19 12.04 7.69  
 20-25 10.47 4.48 8.33 16.67 7.69  
 > 25 26.35 8.96 14.81 49.07 23.08  
Type of practicea
 Clinical 65.54 61.19 63.89 72.22 46.15  
 Academic 61.73 50.75 68.52 9.26 23.08  
 Community 12.84 11.94 12.96 13 15.38  
 Research 19.93 32.84 20.37 12.03 15.38  
 Education 27.36 31.34 22.22 30.56 23.08  
 Administrative 11.49 14.93 12.04 8.33 15.38  
Transplant .351 .2
 Yes 11.82 16.42 22.22 1.85 7.69  
 No 88.18 83.58 77.78 98.15 92.31  
Patient population (n = 168) (n = 26) (n = 31) .086 (n = 103) (n = 8) .351
 Adult 93.45 92.31 90.32 95.15 87.5  
 Pediatric 2.38 0 9.68 1.94 0  
 Both 4.17 7.69 0 2.91 12.5  
aCategories not mutually exclusive.
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reported to bring up issues about fertility more often by 
transplant than nontransplant nephrologists (67% transplant 
vs 45% nontransplant nephrologist, P = .01). Despite respon-
dents reporting that patients wished to discuss concerns asso-
ciated with fertility and menstrual irregularities, only 35% of 
the respondents asked patients to address these concerns 
with their family physician or another physician (endocri-
nologist or gynecologist). This was not different between 
female and male nephrologists (P = .53).
Among allied health care providers, 87% agreed or 
strongly agreed that kidney function has an important impact 
on sex hormone status; however, very few reported always or 
often discussing fertility (7.5%) or menstrual irregularities 
(9%) with their female patients. This was significantly differ-
ent from that reported by physicians (fertility: P < .001; 
menstrual irregularities: P = .04). Twenty-seven percent of 
allied health care providers agreed or strongly agreed that 
their female patients of childbearing age wished to discuss 
fertility often and 30% wished to discuss menstrual abnor-
malities or menopause. Allied health care providers were less 
likely to report that their female patients wished to discuss 
fertility (P < .001) but more likely to report that female 
patients wished to discuss menstrual irregularities (P = .003) 
compared with physicians.
Postmenopausal HT
Forty-three percent of the physicians reported an uncertainty 
for the role for postmenopausal HT in women with CKD; 
17% agreed or strongly agreed that there is a role for HT in 
Figure 1. Nephrologists’ impressions of sex hormone status in chronic kidney disease.
Figure 2. Nephrologists’ impressions of patient discussion of sex hormone status in chronic kidney disease.
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women with CKD. When asked whether the benefits of HT 
outweigh the risks in patients with CKD, 46% of the physi-
cians reported they did not know (Figure 3). Furthermore, 
47% and 45% reported they did not know whether HT should 
be considered in perimenopausal and postmenopausal 
women with CKD, respectively.
Fifty-three percent of the respondents agreed or strongly 
agreed that the formulation of HT and whether it is used in 
conjunction with progesterone are important in women with 
a uterus, and 35% reported they did not know. Similarly, 
37% agreed or strongly agreed that the route of HT adminis-
tration is important, and 37% reported they did not know. 
Thirty-four percent of the physicians agreed or strongly 
agreed that the stage of CKD should be considered for HT 
use while 39% reported they did not know. When asked at 
what stage of CKD the benefits of HT outweigh the risks, 
75% reported they did not know (Figure 4).
Among allied health care professionals, 57% reported 
they did not know whether there is a role for HT in women 
with CKD and 58% reported they did not know whether the 
formulation of HT should be taken into consideration for 
women with CKD. Forty-one percent reported they did not 
know whether the route of administration is important to take 
into consideration for women with CKD.
When asked about HT prescription practice prior to the 
publication of the Women’s Health Initiative (WHI) trials in 
2002,27 47% of the physicians reported they were not in 
nephrology practice prior to 2002, 5.8% reported they often 
prescribed HT, and 37% reported they did not prescribe HT. 
In contrast, 83% stated they did not prescribe HT after the 
WHI trials were published. Among the 5% of physicians 
who provided written comments on HT prescription practice, 
some suggested that they were likely to recommend HT for 
symptom relief in their female patients with CKD (Appendix 
2). Thematic analysis of the comments from the survey is 
presented in Appendix 2.
Discussion
This cross-sectional survey examined the views of nephrolo-
gists and allied health care professionals on the impact of 
kidney disease on sex hormone status. We found that while 
nephrologists and allied health care professionals recognize 
the important effects of kidney disease on sex hormone sta-
tus in women with CKD, reported discussion of the sequelae 
of low estradiol levels such as infertility, menstrual disor-
ders, or premature menopause with their patients was lim-
ited. In addition, there was a high level of uncertainty in the 
nephrology community regarding the role of HT.
There was significant variability in the responses strati-
fied by gender, transplant and nontransplant nephrologists, 
and physicians and allied health care providers. Female 
nephrologists were more likely to report discussing men-
strual irregularities with their patients, and transplant 
nephrologists reported discussing fertility more often than 
nontransplant nephrologists. Physicians were more likely to 
report discussing fertility and menstrual irregularities with 
their female patients than allied health care providers. In 
Figure 3. Nephrologists’ impressions of hormone therapy in CKD.
Note. CKD = chronic kidney disease; HRT = hormone replacement therapy.
Ramesh et al 7
addition, while only 35% of clinicians asked patients to 
address concerns associated with fertility and menstrual 
irregularities with their family doctor or refer them to another 
physician, this could be because few reported often discuss-
ing issues regarding fertility and menstrual irregularities 
with their patients.
Despite awareness that kidney disease–mediated abnor-
malities in sex hormone levels are common, nephrologists 
and allied health care workers reported uncertainties regard-
ing the role for HT in the CKD population. The results of this 
study suggest that while the nephrology community is aware 
of the impact of CKD on sex hormone status with patients, 
incorporation of this knowledge into clinical practice is more 
limited.
In women with CKD, disruptions in GnRH production 
result in an abnormal sex hormone profile leading to low lev-
els of estradiol, though the pathophysiology remains 
unclear.2-4,28,29 Low levels of estradiol result in symptoms 
such as decrease in fertility and sexual desire, menstrual 
abnormalities, hot flashes, sleep disturbances, and mood 
changes which are associated with a decrease in quality of 
life, at least in women without CKD.30-32 Fertility rates 
among women of childbearing age with CKD are low6-8; 
however, complications to both mother and fetus are high 
when pregnancy occurs.10 A study of 100 women with CKD 
reported that 88% had menstrual problems or were meno-
pausal, with 20% of menopausal women being <40 years of 
age.5 A previous cross-sectional study examining gyneco-
logical issues in 76 women on dialysis showed that 59% of 
women reported irregular menses.33 In addition, a meta-anal-
ysis of women with CKD found that the prevalence of sexual 
dysfunction as defined by decreased sexual desire ranged 
from 30% to 80%.34 This suggests that women with CKD 
have a significant burden of signs and symptoms associated 
with low estradiol levels.
There may be several reasons why nephrologists reported 
not often discussing fertility, menstrual irregularities, and 
menopause with their female patients. First, they may feel 
this falls outside their domain of expertise or the primary 
purpose of their clinical encounter with the patient. Second, 
it has been shown that in patients with chronic conditions 
with multiple comorbidities, disease states not prominently 
related to the primary condition are often not addressed.35 
Given the disease burden of the average CKD patient, there 
may be inadequate time to address issues related to sex hor-
mone status.36,37 Third, as suggested by Cochrane and Regan,5 
although nephrologists are often considered the primary care 
provider by their patients,38 women with CKD may not raise 
gynecological issues for discussion with their nephrologists 
as these concerns may appear less important in comparison 
with other kidney-related health issues. Transplant nephrolo-
gists reported discussing fertility with their female patients of 
childbearing age more often than nontransplant nephrolo-
gists. This could be due to the younger age of patients receiv-
ing transplant39 and the recommendation to avoid pregnancy 
within the first 1 to 2 years of transplant, coupled with the 
necessary prescription of potentially teratogenic medications 
in this setting.
Figure 4. Nephrologist impression on factors to consider for hormone therapy in CKD.
Note. CKD = chronic kidney disease; HRT = hormone replacement theory.
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Women with kidney disease experience cessation of men-
ses significantly earlier than do the general population, and 
while there are no CKD-specific recommendations, interna-
tional guidelines suggest that women with premature meno-
pause initiate HT until the natural age of menopause.15-18 Our 
survey highlights that nephrologists and other allied health 
care providers are not confident discussing or prescribing HT 
in women with CKD. The knowledge gap on this issue likely 
reflects the paucity of literature on HT in this population; few 
studies have examined the role of HT specifically in women 
with kidney disease.19-25 It is possible that discussion of clini-
cal sequelae of low estrogen levels is limited due to lack of 
evidence for a viable treatment option in this population. 
Further clinical trials are required to determine the effective-
ness and safety of postmenopausal HT in women with CKD.
When and how to incorporate discussion regarding con-
traception, fertility, and menopause with the female CKD 
patient is beyond the scope of this study. However, raising 
these issues common to all women as part of the initial con-
sult would ensure that patients and their health care providers 
recognize that kidney disease has an important impact on 
sexual, hormonal, and gynecologic aspects to their care.
Limitations
The limitations of our survey include the self-reported nature 
of the data, as well as the possibility of differences in practice 
between respondents and nonrespondents. The generalizabil-
ity of our study may be limited. First, the physician sample 
self-identified as mainly nephrologists in academic practice 
and was derived through membership to nephrology societies 
of high-income countries, which may not accurately capture 
global practice. Second, the survey response rate was low; 
however, our average response rate of 21% is comparable with 
the typical 20% response rate to online surveys of clinicians.40,41 
Third, the majority of respondents were from the Canadian 
societies, and thus, the results of the survey primarily reflect 
perceptions from a Canadian perspective. Our sample may be 
enriched for female nephrologists, because 38% of the 
nephrologist respondents were women, as compared with a 
recent estimate of the proportion of female nephrologists 
(34%).42 This was a preliminary survey designed to determine 
the initial impressions of nephrologists on the impact of sex 
hormones on CKD; as such, questions exploring reasons for 
the lack of discussion on CKD and sex hormones in a clinical 
setting were not explored. Further studies are required to better 
understand the conclusions of this study. This study is also 
limited by the lack of objective definitions of options like 
often and rarely; however, to avoid floor and ceiling effects of 
this Likert scale, we included several options in the Likert 
scale and an open-ended comment section. Nephrology prac-
tices commonly include elderly populations, and it is possible 
that increased patient age may play a role in the reported lack 
of discussion of sex hormone status and its sequelae; however, 
the survey questions were specific to age-appropriate patient 
populations. Lastly, studies have suggested that social desir-
ability bias results in the tendency of survey respondents to 
answer questions in a manner that will be viewed favorably by 
others43; thus, actual discussion rates of issues related to sex 
hormone status in women with CKD may be lower. However, 
a recent meta-analysis has suggested that computer-based sur-
vey may limit social desirability bias,44 though this has been 
disputed.43
Conclusion
In an international survey of nephrologists and renal allied 
health care providers, we found that while physicians and 
allied health care providers were aware of the impact of CKD 
on sex hormone levels, discussion and management of men-
strual irregularities, fertility, and menopausal status were 
reported to be relatively infrequent. There was a high level of 
uncertainty among nephrologists with regard to the role of 
HT in women with CKD. In identifying this important 
knowledge and practice gap, we have highlighted the need 
for further study of this common clinical issue in women 
with CKD and the need for education for clinicians and allied 
health care providers on advising women with CKD on infer-
tility and menopause.
Appendix 1: Survey
Sex Hormones in Chronic Kidney Disease
I understand the above stated purpose of this survey and 
consent to the use of my responses for the purpose of aca-
demic research:
 ○ Yes
 ○ No
Demographic Information
1. Age
 ○ 30-40 Years
 ○ 41-50 Years
 ○ 51-60 Years
 ○ 61-70 Years
 ○ >70 Years
2. Sex
 ○ Male
 ○ Female
3. Years of Practice
 ○ 5-10 Years
 ○ 10-15 Years
 ○ 15-20 Years
 ○ 20-25 Years
 ○ 25 Years
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4. How are you involved in nephrology practice?
 ○ Nephrologist
 ○ Medical trainee in nephrology
 ○ Nurse practitioner
 ○ Nurse
 ○ Other (please specify) ______________________
5. Type of Practice (check all that apply)
  Academic
  Community
  Clinical
  Education
  Administrative
  Research
  Other (Please Specify) ______________________
6. Are you a transplant nephrologist?
 ○ Yes
 ○ No
7. What type of patients are in your practice?
 ○ Pediatric
 ○ Adult
 ○ Both
Please answer the following based on your personal clini-
cal practice
1.  How often do you discuss fertility with your female 
patients of childbearing age? (Number of comments: 31)
 ○ Never
 ○ Rarely
 ○ Sometimes
 ○ Often
 ○ Always
Comments (optional)
2.  How often do you discuss menstrual irregularities 
with your female patients of childbearing age? 
(Number of comments: 17)
 ○ Never
 ○ Rarely
 ○ Sometimes
 ○ Often
 ○ Always
Comments (optional)
3.  How often do you ask patients to address concerns 
associated with fertility and menstrual irregularities 
with their family doctor or refer them to another 
physician (endocrinologists or gynecologists)? 
(Number of comments: 13)
 ○ Never
 ○ Rarely
 ○ Sometimes
 ○ Often
 ○ Always
Comments (optional)
 To what extent do you agree or disagree with the follow-
ing statements:
4.  Kidney function has an important impact on sex 
hormone levels, menstrual status, and fertility. 
(Number of comments: 3)
 ○ Strongly Agree
 ○ Agree
 ○ Neutral
 ○ Disagree
 ○ Strongly Disagree
 ○ I Do Not Know
Comments (optional)
5.  My female patients of childbearing age often wish to 
discuss fertility. (Number of comments: 15)
 ○ Strongly Agree
 ○ Agree
 ○ Neutral
 ○ Disagree
 ○ Strongly Disagree
Comments (optional)
6.  My female patients under the age of 55 often wish to 
discuss menstrual status and symptoms or treat-
ment of menopause. (Number of comments: 13)
 ○ Strongly Agree
 ○ Agree
 ○ Neutral
 ○ Disagree
 ○ Strongly Disagree
Comments (optional)
7.  There is a role for postmenopausal hormone replace-
ment therapy (HRT) in patients with CKD. (Number 
of comments: 15)
 ○ Strongly Agree
 ○ Agree
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 ○ Neutral
 ○ Disagree
 ○ Strongly Disagree
 ○ I Do Not Know
Comments (optional)
8.  The benefits of HRT far outweigh the risks in 
patients with CKD. (Number of comments: 12)
 ○ Strongly Agree
 ○ Agree
 ○ Neutral
 ○ Disagree
 ○ Strongly Disagree
 ○ I Do Not Know
Comments (optional)
9.  In women with a uterus, the formulation of the hor-
mone therapy and whether it used in conjunction with 
progesterone is important. (Number of comments: 6)
 ○ Strongly Agree
 ○ Agree
 ○ Neutral
 ○ Disagree
 ○ Strongly Disagree
 ○ I Do Not Know
Comments (optional)
10.  The route of administration of HRT (oral, trans-
dermal, transvaginal) is important. (Number of 
comments: 2)
  ○ Strongly Agree
  ○ Agree
  ○ Neutral
  ○ Disagree
  ○ Strongly Disagree
  ○ I Do Not Know
Comments (optional)
11.  I often prescribed HRT PRIOR to the Women’s 
Health Initiative (WHI) trials (JAMA 2002). 
(Number of comments: 18)
  ○ Strongly Agree
  ○ Agree
  ○ Neutral
  ○ Disagree
  ○ Strongly Disagree
  ○ I Do Not Know
  ○ I was not in nephrology practice prior to 2002
Comments (optional)
12.  I often prescribe HRT AFTER the Women’s Health 
Initiative (WHI) trials (JAMA 2002). (Number of 
comments: 28)
  ○ Strongly Agree
  ○ Agree
  ○ Neutral
  ○ Disagree
  ○ Strongly Disagree
  ○ I Do Not Know
Comments (optional)
13.  Stage of CKD is important when considering HRT 
use. (Number of comments: 6)
  ○ Strongly Agree
  ○ Agree
  ○ Neutral
  ○ Disagree
  ○ Strongly Disagree
  ○ I Do Not Know
Comments (optional)
14.  The benefits of HRT outweigh the risks in the fol-
lowing stages of CKD (check all that apply). 
(Number of comments: 9)
   Stage 1 CKD
   Stage 2 CKD
   Stage 3a CKD
   Stage 3b CKD
   Stage 4 CKD
   Stage 5 CKD
   Stage 5 D CKD
   I do not know
    HRT should never be prescribed to CKD 
patients
Comments (optional)
Ramesh et al 11
15.  HRT use should be considered in perimeno-
pausal women with CKD. (Number of com-
ments: 12)
  ○ Strongly Agree
  ○ Agree
  ○ Neutral
  ○ Disagree
  ○ Strongly Disagree
  ○ I Do Not Know
Comments (optional)
16.  HRT use should be considered in postmenopausal 
women with CKD. (Number of comments: 17)
  ○ Strongly Agree
  ○ Agree
  ○ Neutral
  ○ Disagree
  ○ Strongly Disagree
  ○ I Do Not Know
Comments (optional)
Appendix 2: Thematic Analysis
 1. How often do you discuss fertility with your female 
patients of childbearing age? (n = 31)
 2. How often do you discuss menstrual irregularities 
with your female patients of childbearing age? 
(n = 17)
 3. How often do you ask patients to address concerns 
associated with fertility and menstrual irregularities 
with their family doctor or refer them to another phy-
sician (endocrinologists or gynecologists)? (n = 13)
 4. Kidney function has an important impact on sex hor-
mone levels, menstrual status, and fertility. (n = 3)
 5. 
My female patients of childbearing age often wish to 
discuss fertility. (n = 15)
 6. My female patients under the age of 55 often wish to 
discuss menstrual status and symptoms or treatment 
of menopause. (n = 13)
 7. There is a role for postmenopausal hormone replace-
ment therapy (HRT) in patients with CKD. (n = 16)
 8. The benefits of HRT far outweigh the risks in patients 
with CKD. (n = 12)
 9. In women with a uterus, the formulation of the hor-
mone therapy and whether it used in conjunction 
with progesterone is important. (n = 10)
10. The route of administration of HRT (oral, transder-
mal, transvaginal) is important. (n = 2)
11. I often prescribed HRT PRIOR to the Women’s 
Health Initiative (WHI) trials (JAMA 2002). (n = 18)
All comments regarding not being licensed to prescribe
Fertility discussed if prescribing angiotensin converting 
enzyme inhibitor or angiotension receptor blocker
Fertility discussed if patient was undergoing a transplant 
or post transplant
Fertility discussed if patient was having 
immunosuppression
Patient asked to discuss this with general practitioner
If patient has dysmenorrhea
Referred for discussing birth control
Referred based on patient concerns
Not aware of any associations
Patient dependent
Patients want to talk post-transplant
Depends on stage of CKD
Patients only bring it up if significant symptoms occur
Patients bring it up in pre-dialysis clinic
Only in symptomatic women
Lack of strong evidence supporting HRT
Have to take cardiovascular risk into consideration
Not according to recommendations or evidence
CKD patients have a higher risk than the general 
population
Dependent on quality of life versus heart disease
Similar to the general population
Have to consider long term risk of malignancy
Not aware for CKD population
Patient dependent
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12. I often prescribe HRT AFTER the Women’s Health 
Initiative (WHI) trials (JAMA 2002). (n = 28)
All comments regarding not being licensed to prescribe
13. Stage of CKD is important when considering HRT 
use. (n = 6)
14. The benefits of HRT outweigh the risks in the follow-
ing stages of CKD (check all that apply). (n = 9)
15. HRT use should be considered in perimenopausal 
women with CKD. (n = 12)
16. HRT use should be considered in postmenopausal 
women with CKD. (n = 17)
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